Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤Q3 net revenue $45.5 million, down 70% year over year
- ➤Advanced Wound Care revenue $38.2 million, down 73%
- ➤Q3 net loss $29.6 million versus $21.6 million net income
- ➤2026 revenue guidance $179.4 million-$200.0 million, down 65%-68%
- ➤Cash, equivalents and restricted cash fell to $26.9 million
Expert Statements
Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board, Organogenesis
“We continue to strengthen our position as a leader in regenerative medicine as customers choose a partner and products they trust.”
Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board, Organogenesis
“Third quarter revenue increased sequentially, and our market share gains are broad-based across our portfolio.”
Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board, Organogenesis
“We are defining a sustainable future for advanced wound care as we emerge from the market reset a stronger company anchored by evidence-based living cell products that we believe will be the cornerstone of the market going forward.”
CANTON, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2026.
Third Quarter 2026 Financial Results Summary: * Net revenue of $45.5 million for the third quarter of 2026, a decrease of $105.0 million compared to net revenue of $150.5 million for the third quarter of 2025. Net revenue for the third quarter of 2026 consists of: * Net revenue from Advanced Wound Care products of $38.2 million, a decrease of 73% from the third quarter of 2025. * Net revenue from Surgical & Sports Medicine products of $7.3 million, a decrease of 19% from the third quarter of 2025.
Get started
Create a free account to read the full story.